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Background: Predictive models to identify unknown methicillin-resistant Staphylococcus aureus (MRSA) carriage on
admission may optimise targeted MRSA screening and efficient use of resources. However, common approaches to
model selection can result in overconfident estimates and poor predictive performance. We aimed to compare the
performance of various models to predict previously unknown MRSA carriage on admission to surgical wards.
Methods: The study analysed data collected during a prospective cohort study which enrolled consecutive adult
patients admitted to 13 surgical wards in 4 European hospitals. The participating hospitals were located in Athens
(Greece), Barcelona (Spain), Cremona (Italy) and Paris (France). Universal admission MRSA screening was performed
in the surgical wards. Data regarding demographic characteristics and potential risk factors for MRSA carriage were
prospectively collected during the study period. Four logistic regression models were used to predict probabilities
of unknown MRSA carriage using risk factor data: “Stepwise” (variables selected by backward elimination); “Best
BMA” (model with highest posterior probability using Bayesian model averaging which accounts for uncertainty in
model choice); “BMA” (average of all models selected with BMA); and “Simple” (model including variables
selected >50% of the time by both Stepwise and BMA approaches applied to repeated random sub-samples of
50% of the data). To assess model performance, cross-validation against data not used for model fitting was
conducted and net reclassification improvement (NRI) was calculated.
Results: Of 2,901 patients enrolled, 111 (3.8%) were newly identified MRSA carriers. Recent hospitalisation and presence
of a wound/ulcer were significantly associated with MRSA carriage in all models. While all models demonstrated limited
predictive ability (mean c-statistics <0.7) the Simple model consistently detected more MRSA-positive individuals despite
screening fewer patients than the Stepwise model. Moreover, the Simple model improved reclassification of patients into
appropriate risk strata compared with the Stepwise model (NRI 6.6%, P = .07).
Conclusions: Though commonly used, models developed using stepwise variable selection can have relatively poor
predictive value. When developing MRSA risk indices, simpler models, which account for uncertainty in model selection,
may better stratify patients’ risk of unknown MRSA carriage.
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Mandatory universal methicillin-resistant Staphylococcus
aureus (MRSA) screening has been introduced in healthcare
facilities in many countries, including parts of Europe [1,2].
Recent evidence, however, demonstrates that this approach
is not cost-effective in low prevalence settings [3-6] and all
European countries have now abandoned mandatory univer-
sal MRSA screening. Instead, targeted screening has been
advocated. The success of this strategy, however, relies on
the development of well-validated MRSA risk indices to
guide selection of patients for screening. This is particularly
important in surgical wards where appropriate use of peri-
operative prophylaxis and decolonisation for MRSA carriers
may significantly reduce surgical site infections [7-9].
Statistical models have been used to develop risk pre-
diction systems to identify potential MRSA carriers for
screening [10-17]. Despite their widespread use, common
approaches to prediction modelling, such as stepwise re-
gression, ignore the uncertainty in model selection which
can result in overconfident estimates and poor predictive
accuracy [18,19]. These limitations may be addressed with
other variable selection methods such as model averaging
[19]. To our knowledge, no studies have reported the clin-
ical implications of using different model selection tech-
niques for developing MRSA risk indices.
We aimed to compare the performance of various models
to predict previously unknown MRSA carriage on admission
to surgical wards in 4 European hospitals. We hypothesised
that the predictive ability of the commonly-used multivari-
able stepwise logistic regression method is inferior to other
approaches, such as Bayesian model averaging, which ac-
count for model uncertainty.Methods
Study design and setting
This study analysed data collected from a prospective cohort
study conducted in 13 surgical wards of 4 hospitals in
4 European countries (Athens, Greece; Barcelona, Spain;
Cremona, Italy; and Paris, France) [20]. The enrolled wards
included vascular (4), orthopaedic (4), cardiac (2), general
(2) and neurosurgery (1) subspecialties. The number of an-
nual admissions to the surgical wards at each hospital
ranged from 2,723 in Paris to 3,932 in Cremona, with the
annual number of surgical procedures ranging from 1,792 in
Athens to 3,083 in Paris. Universal MRSA screening on ad-
mission was performed on these wards between December
2008 and January 2010. Consecutive adult patients admitted
to these wards during this time were eligible for study enrol-
ment. Patients were excluded if they were admitted for less
than 24 hours or not screened within 48 hours of admission.
Patients already known to be MRSA colonised or infected
were also excluded as we were interested in risk profiling pa-
tients to identify previously unknown MRSA carriers.MRSA screening
MRSA screening swabs were collected from the nose,
perineum and wounds if present. Swabs were inoculated
directly onto an MRSA chromogenic medium (BBL
CHROMagar MRSA II, BD Diagnostics, Belgium) as well
as being placed in an enrichment broth to increase the
sensitivity of MRSA detection [21]. After incubation at
37°C for 20–24 hours, any characteristically coloured
colonies on the chromogenic media were subcultured onto
blood agar and incubated overnight. The tube coagulase
test, mannitol salt agar subculture and/or the latex agglu-
tination test were used to confirm isolates as S. aureus.
The enrichment broth, after overnight incubation, was in-
oculated onto MRSA chromogenic medium if the results
of direct plating were negative or indeterminate, then the
same procedure as for direct plating was followed.
Screening specimens were processed in local microbiol-
ogy laboratories which participated in an external quality
assurance program [22]. Confirmation of MRSA identifi-
cation and susceptibility testing was also performed at the
study’s central laboratory at the University of Antwerp,
Belgium.
Data collection
Data regarding demographic characteristics, comorbidities
and potential risk factors for MRSA carriage were col-
lected using a standardised case report form. These data
included age, sex, surgical subspecialty, chronic medical
conditions, hospitalisation in the last year, surgery in the
last 3 months, history of transfer from another ward or
healthcare facility, nursing home residency, presence of a
skin wound or pressure sore, antibiotic use in the last
6 months and the presence of long-term invasive devices.
The primary outcome of interest was previously unknown
MRSA colonisation on admission defined as the detection
of MRSA from a screening swab or clinical sample collected
within 48 hours of admission to the surgical ward.
Statistical analysis
Univariable analyses of baseline characteristics were per-
formed using χ2 test or Student’s t-test as appropriate. For
the multivariable analysis, we compared the commonly
used stepwise variable selection approach with Bayesian
model averaging (BMA) which provides a mechanism for
accounting for model uncertainty with the aim of improv-
ing prediction accuracy [18,19]. The stepwise approach in-
volved stepwise backward logistic regression with inclusion
of all covariates with P < .2 in the primary model. Likeli-
hood ratio tests were used to guide exclusion of covariates
from the model. Covariates with P ≤ .05 were retained in
the model. The BMA approach averaged over multiple
models and used the posterior probabilities of these
models to perform all inferences and predictions [19]. We
developed 4 multivariable logistic regression models: 1)
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ation; 2) “Best BMA” model – which was the model with
the highest posterior probability after using the Bayesian
model averaging approach; 3) “BMA” model – which in-
cluded all covariates with a posterior probability greater
than zero with Bayesian model averaging; 4) “Simple”
model – which included covariates selected at least half
the time in both Stepwise and BMA models on repeated
random sub-samples of 50% of the data from the whole
cohort. The aim of the “Simple” model strategy was to de-
velop a simple or parsimonious model with a clinically
meaningful level of prediction with as few predictor vari-
ables as possible. All tests were 2-tailed and P ≤ .05 was
considered statistically significant.
To evaluate the predictive performance of the models,
cross-validation was performed using 1000 repeated ran-
dom sub-samples of the data of the entire cohort divided
in a 1:1 ratio into derivation and validation datasets.
Models were constructed with the first half of the data
(derivation dataset). The results of this analysis were then
used to predict unknown MRSA carriage in the other half
of the data (validation dataset). The c-statistic (or area
under the receiver operating characteristic (ROC) curve
which plots sensitivity against 1-specificity) was calculated
to determine the models’ ability to discriminate between
individuals who were and were not MRSA colonised. The
c-statistic has a theoretical range from 0 to 1, with a statis-
tically meaningful range from 0.5 (no predictive ability) to
1 (perfect discrimination) [23]. A mean c-statistic was cal-
culated from the logistic models fitted to the derivation
cohorts from the repeated random sub-samples of the
data. To assess the agreement between predicted and ob-
served MRSA carriage, the relative frequencies of pre-
dicted probabilities (density plots) of MRSA colonisation
were plotted by observed MRSA colonisation status as de-
termined by admission screening. Because the derivation
and validation datasets are from the same 4 hospitals, the
results may overestimate the likely predictive performance
when applied to other hospitals. To overcome this prob-
lem, models were fitted using data from 3 of 4 hospitals as
the derivation dataset with each hospital in turn being
used as the validation dataset.
Similarly, the clinical utility of the models was evaluated
by selecting a random sample of 50% of the full cohort as
the derivation dataset and using the remaining data as the
validation dataset. We calculated the sensitivity, specificity,
positive predictive value (PPV) and negative predictive
value (NPV) for screening patients at varying levels of pre-
dicted probabilities of MRSA carriage as determined by
the 4 models. We then used a cut-off of 4% predicted
probability of MRSA carriage to categorise patients as
low- or high-risk using the Stepwise model. The accuracy
with which each model stratified risk was compared with
that of the Stepwise model by calculating the number ofpatients who were reclassified into different risk categories
using each model [23]. Any upward movement in pre-
dicted risk for subjects with MRSA implied improved re-
classification, and any downward movement indicated
worse reclassification. The opposite applied for MRSA
negative subjects. The improvement in reclassification was
quantified as the net reclassification improvement (NRI)
(sum of differences in proportion of individuals moving
up minus the proportion moving down for those with
MRSA, and the proportion of individuals moving down
minus the proportion moving up for those without
MRSA) [24]. The analyses were performed with R statis-
tical software including the BMA package [25,26].
Ethics statement
The study was approved by the Institutional Review Board
of the University of Geneva Hospitals (Comité d’Ethique
N.A.C.), the location of the coordinating centre. Local eth-
ics committee approval was also obtained from each par-
ticipating hospital as a quality improvement project with a
waiver of individual informed consent (Institution Review
Board of Laiko General Hospital, Athens; Comité Etico
de Investigación Clínica, Barcelona; Comitato Etico degli
Istituti Ospitalieri di Cremona, Cremona; Comité de
Protection des Personnes – Ile-de-France IX, Paris).
Results
There were 2,935 patients screened on admission to the
surgical wards. Among these, 34 (1.2%) patients were ex-
cluded as they were previously known to be MRSA colo-
nised or infected. The remaining 2,901 patients were
included in the study, of which 111 (3.8%) were newly
identified MRSA carriers. Patient characteristics are shown
in Table 1. Risk factors for MRSA carriage on admission
on univariable analysis included older age, cerebrovascular
disease, diabetes mellitus, chronic obstructive pulmonary
disease, chronic skin disease, hospitalisation in the last
year, nursing home residency, presence of a skin wound or
pressure sore, antibiotic use in the last 6 months, urinary
catheterisation and presence of a tracheostomy.
Multivariable models
Independent predictors of MRSA carriage on admission
for each multivariable model are shown in Table 2. Recent
hospitalisation and the presence of a wound or pressure
sore were significantly associated with MRSA carriage in
all models. The Stepwise model identified 6 independent
risk factors for MRSA colonisation (older age, chronic skin
disease, hospitalisation in the last year, nursing home resi-
dency, presence of a wound or pressure sore and urinary
catheterisation). The covariates in the first 27 models se-
lected by the BMA approach are illustrated in Figure 1.
The Best BMA model, the model with the highest poster-
ior probability (Model #1 in Figure 1), included nursing
Table 1 Characteristics of patients colonised and not
colonised with methicillin-resistant Staphylococcus aureus
on admission
Characteristic MRSA positive MRSA negative P
(n = 111) (n = 2,790)
Hospital <.001
Athens (n = 985) 51 (5.2) 934 (94.8)
Barcelona (n = 510) 9 (1.8) 501 (98.2)
Cremona (n = 817) 20 (2.4) 797 (97.6)
Paris (n = 589) 31 (5.3) 558 (94.7)
Age, mean (SD), years 70.3 (16.5) 64.5 (17.9) <.001
Female sex 59 (53.2) 1,358 (48.7) .355
Surgical subspecialty .112
General 29 (26.1) 639 (22.9)
Vascular 31 (27.9) 779 (27.9)
Neurosurgery 7 (6.3) 229 (8.2)
Orthopaedics 42 (37.8) 910 (32.6)
Cardiothoracic 2 (1.8) 233 (8.4)
Comorbidities
Chronic renal failure 8 (7.2) 131 (4.7) .224
Haemodialysis 1 (0.9) 27 (1.0) .944
Cardiovascular disease 69 (62.2) 1,584 (56.8) .261
Cerebrovascular disease 4 (3.6) 33 (1.2) .026
Diabetes mellitus 34 (30.6) 471 (16.9) <.001
COPD 19 (17.1) 273 (9.8) .012
Solid organ malignancy 18 (16.2) 402 (14.4) .596
Haematological malignancy 1 (0.9) 10 (0.4) .362
Autoimmune disease 1 (0.9) 63 (2.3) .340
Liver cirrhosis 4 (3.6) 58 (2.1) .276
HIV infection 0 (0.0) 11 (0.4) .507
Trauma 24 (21.6) 554 (19.9) .648
Chronic skin disease 12 (10.8) 98 (3.5) <.001
Recent hospitalisation (<1 year) 60 (54.1) 862 (30.9) <.001
Recent surgery (<3 months) 17 (15.3) 277 (9.9) .065
Transfer from another ward or
hospital
8 (7.2) 231 (8.3) .687
Nursing home resident 11 (9.9) 75 (2.7) <.001
Skin wound/ulcer 26 (23.4) 200 (7.2) <.001
Recent antibiotic use (<6 months) 47 (42.3) 674 (24.2) <.001
Indwelling devices
Long-term vascular catheter 1 (0.9) 22 (0.8) .896
Urinary catheter 8 (7.2) 42 (1.5) <.001
Tracheostomy 3 (2.7) 17 (0.6) .009
Other device 2 (1.8) 53 (1.9) .941
Note. Data are no. (%) of patients unless otherwise indicated. COPD, chronic
obstructive pulmonary disease; HIV, human immunodeficiency virus; MRSA,
methicillin-resistant Staphylococcus aureus; SD, standard deviation.
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to the 2 risk factors selected in all models. The BMA
model, which averaged over the multiple selected models,
only identified the 2 risk factors common to all models as
significant but included 10 risk factors in total. In the Sim-
ple model, MRSA carriage was associated with 5 covari-
ates (those of the Stepwise model excluding urinary
catheterisation).Assessment of the performance of the prediction models
After cross-validation, the mean c-statistics were 0.643
(SD 0.029) for the Stepwise model, 0.663 (SD 0.028) for
the Best BMA model, 0.653 (SD 0.031) for the BMA
model, and 0.687 (SD 0.030) for the Simple model
(Table 2), demonstrating limited ability of all the models
to discriminate between patients who were and were not
MRSA colonised. The ROC curves for all models were
similar, though showed that the Stepwise model consist-
ently had the worst performance and the Simple model
was consistently best (Figure 2). The density plots in
Figure 3 also show that there is considerable overlap
between MRSA positive and negative patients for the
range of probabilities of MRSA carriage predicted by
the models, particularly for low predicted probabilities.
When each hospital was used in turn as the validation
cohort, the Simple model was again most discriminatory
in all models (c-statistics in Table 2). However, these
models performed less well than the models that were fit-
ted to data from the whole cohort. The discrimination of
the models was in the poor to limited range (c-statistics
0.579 to 0.686) except when the models were validated in
the Barcelona cohort where the models had higher c-stat-
istic values (0.762 to 0.798).
Table 3 summarises the changes in screening perform-
ance with the use of different cut-offs of predicted prob-
ability of MRSA carriage. For all cut-offs, the Simple
model detected more MRSA-positive patients than the
Stepwise model despite screening fewer patients in total,
giving an improvement in PPV of up to 15%. Targeted
screening of patients with a predicted MRSA carriage
risk of greater than or equal to 4% would result in simi-
lar reduction in screening volume using all four models
(64% to 68%). For this cut-off, the sensitivity for detect-
ing MRSA carriers ranged from 61% to 69%, with the
lowest sensitivity for the Stepwise model and the highest
for the Best BMA model. The Simple model, however,
had the highest PPV, on account of the smaller number of
patients screened, while the Stepwise model had the low-
est PPV. At higher cut-offs, larger differences between
models were seen. For example, with a cut-off of 6%, the
Best BMA model would screen 45% fewer patients than
the Stepwise model, but detect only one fewer MRSA pa-
tient, corresponding to a 70% improvement in the PPV.
Table 2 Results of multivariable models of risk factors for methicillin-resistant Staphylococcus aureus carriage on
admission
Risk factor Stepwise model Best BMA model BMA model Simple model
OR 95% CI P OR 95% CI P Posterior Probability OR 95% CI P OR 95% CI P
Female sex 2.3 1.0 0.9-1.1 .894
Age (per 1-year increment) 1.02 1.00-1.03 .009 44.8 1.01 0.99-1.03 .421 1.02 1.00-1.03 .009
Diabetes 7.8 1.0 0.8-1.4 .796
Chronic skin disease 3.0 1.5-5.8 .002 49.3 1.7 0.5-5.3 .369 2.9 1.5-5.6 .002
Hospitalisation (<1 year) 2.2 1.5-3.3 <.001 2.3 1.5-3.4 <.001 100 2.2 1.5-3.4 <.001 2.2 1.5-3.3 <.001
Nursing home resident 3.4 1.6–6.8 .001 4.2 2.1-8.3 <.001 82.4 3.1 0.9-10.3 .070 3.4 1.7-6.9 .001
Skin wound/sore 2.7 1.7-4.4 <.001 3.0 1.8-4.8 <.001 100 2.9 1.7-4.7 <.001 2.8 1.7-4.6 <.001
Antibiotics (<6 months) 2.6 1.0 0.9-1.2 .890
Urinary catheter 4.5 2.0-10.3 .018 4.3 1.9-9.6 <.001 72.4 2.9 0.7-12.8 .152
Tracheostomy 3.1 1.1 0.6-2.0 .867
C-statistics for validation dataset
Cross-validation, mean (SD)a 0.643 (0.029) 0.663 (0.028) 0.653 (0.031) 0.687 (0.030)
Athens 0.598 0.610 0.606 0.640
Barcelona 0.762 0.797 0.798 0.797
Cremona 0.585 0.641 0.601 0.670
Paris 0.585 0.579 0.627 0.686
Note. The Stepwise model used stepwise backward elimination; the Best BMA model was the model with the highest posterior probability with the Bayesian
model averaging approach; the BMA model included all covariates with a posterior probability of greater than zero using Bayesian model averaging; the Simple
model included variables selected at least half the time in both Stepwise and BMA models on repeated random sub-samples of 50% of the cohort. CI, confidence
interval; OR, odds ratio; SD, standard deviation.
aCross-validation by repeated random sub-sampling of 50% of the full cohort data for derivation and validation datasets.
Female sex
Age
Chronic renal failure
Haemodialysis
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Figure 1 Methicillin-resistant Staphylococcus aureus predictors selected in various models by Bayesian model averaging. Note. HIV,
human immunodeficiency virus.
Lee et al. BMC Infectious Diseases  (2015) 15:105 Page 5 of 10
Stepwise model 
Best BMA model
BMA model 
Simple model 
Figure 2 Receiver operating characteristic (ROC) curves for the
multivariable models of admission methicillin-resistant
Staphylococcus aureus carriage. Note. BMA, Bayesian model averaging.
Stepwise Model 
BMA Model 
Figure 3 Density plots showing the relative frequencies of predicted
aureus colonisation. Note. BMA, Bayesian model averaging.
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this cohort (3.8%), all models had high NPVs.
Using a cut-off of 4% for the predicted probability of
MRSA carriage led to the classification of 482 of 1,451
(33.2%) patients in the validation cohort as high-risk
with the Stepwise model. Table 4 shows how patients
are reclassified into risk groups for each model com-
pared with the Stepwise model for this cut-off. The
measure of correct reclassification (NRI) was 5.2%
(95% CI −6.3%-16.6%, P = .38) for the Best BMA model
compared to the Stepwise model, indicating that 5.2% more
MRSA positive patients were appropriately moved up a risk
category than down compared to MRSA negative patients.
The NRIs were 5.6% (95% CI −3.4%-14.6%, P = .22) and
6.6% (95% CI −0.5%-13.6%, P = .07) for the BMA and Sim-
ple models compared to the Stepwise model, respectively.
Discussion
The development of a successful targeted MRSA screening
strategy requires a robust tool for identifying individuals at
increased risk of MRSA carriage. Prediction models can
quantify this risk and therefore facilitate screening ofSimple Model 
Best BMA Model 
probabilities of admission methicillin-resistant Staphylococcus
Table 3 Comparison of methicillin-resistant Staphylococcus aureus (MRSA) screening strategies using different
predictive models
Cut-off for screening No. of patients to
be screened (%)
No. of patients
MRSA positive
Sensitivity (%) Specificity (%) PPV (%) NPV (%)
Universal screening 1,451 (100) 49 100 0 3.4 -
Predicted probability≥ 2%
Stepwise model 1,213 (83.6) 46 93.9 16.8 3.8 98.7
Best BMA model 1,451 (100) 49 100 0 3.4 -
BMA model 1,437 (99.0) 49 100 1.0 3.4 100
Simple model 1,201 (82.8) 47 95.9 17.7 3.9 99.2
Predicted probability≥ 3%
Stepwise model 813 (56.0) 37 75.5 44.7 4.6 98.1
Best BMA model 528 (36.4) 34 69.4 64.8 6.4 98.4
BMA model 1,137 (78.4) 44 89.8 22.0 3.9 98.4
Simple model 776 (53.5) 39 79.6 47.4 5.0 98.5
Predicted probability≥ 4%
Stepwise model 482 (33.2) 30 61.2 67.8 6.2 98.0
Best BMA model 528 (36.4) 34 69.4 64.8 6.4 98.4
BMA model 463 (31.9) 31 63.3 69.2 6.7 98.2
Simple model 479 (33.0) 33 67.3 68.2 6.9 98.4
Predicted probability≥ 5%
Stepwise model 354 (24.4) 26 53.1 76.6 7.3 97.9
Best BMA model 167 (11.5) 19 38.8 89.4 11.4 97.7
BMA model 133 (9.2) 16 32.7 91.7 12.0 97.5
Simple model 336 (23.2) 27 55.1 78.0 8.0 98.0
Predicted probability≥ 6%
Stepwise model 229 (15.8) 18 36.7 85.0 7.9 97.5
Best BMA model 126 (8.7) 17 34.7 92.2 13.5 97.6
BMA model 64 (4.4) 6 12.2 95.9 9.4 96.9
Simple model 220 (15.2) 20 40.8 85.7 9.1 97.6
Note. The table shows the results when a random sample of 50% of the full cohort was used as the derivation dataset with the remaining data used as the
validation dataset. MRSA, methicillin-resistant Staphylococcus aureus; NPV, negative predictive value; PPV, positive predictive value.
Table 4 Reclassification in predicted risk of methicillin-resistant Staphylococcus aureus carriage between models
Stepwise model Best BMA model BMA model Simple model
Frequency (Row %) <4% ≥4% Total <4% ≥4% Total <4% ≥4% Total
Patients who screened MRSA positive
<4% 13 (68.4) 6 (31.6) 19 16 (84.2) 3 (15.8) 19 16 (84.2) 3 (15.8) 19
≥4% 2 (6.7) 28 (93.3) 30 2 (6.7) 28 (93.3) 30 0 (0) 30 (100) 30
Total 15 34 49 18 31 49 16 33 49
Patients who screened MRSA negative
<4% 852 (89.7) 98 (10.3) 950 917 (96.5) 33 (3.5) 950 915 (96.3) 35 (3.7) 950
≥4% 56 (12.4) 396 (87.6) 452 53 (11.7) 399 (88.3) 452 41 (9.1) 411 (90.9) 452
Total 908 494 1,402 970 432 1,402 956 446 1,402
NRI (95% CI) 5.2% (−6.3%-16.6%) P = .376 5.6% (−3.4%-14.6%) P = .222 6.6% (−0.5%-13.6%) P = .068
Note. The table shows the results when a random sample of 50% of the full cohort was used as the derivation dataset with the remaining data used as the
validation dataset. CI, confidence interval; MRSA, methicillin-resistant Staphylococcus aureus; NRI, net reclassification improvement of each model compared with
the Stepwise model.
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with the ultimate aim of increasing the cost-effectiveness of
the screening strategy [12]. We compared different model-
ling approaches and found that the predictive performance
of the models to identify unknown MRSA carriage on ad-
mission to surgical wards was limited. However, when we
assessed model performance using cross-validation, we
were able to demonstrate that the commonly-used stepwise
model selection approach has inferior predictive perform-
ance to approaches that account for model uncertainty.
There is no consensus on the optimal approach to
building a multivariable predictive model [27]. Alterna-
tive methods to stepwise variable selection include use
of full(er) models which leave non-significant variables in
the model, expert knowledge to guide variable selection
and automated approaches such as Lasso and Least
Angle Regression (LAR) methods [28]. Each approach
has its advantages and disadvantages. We specifically
set out to compare stepwise logistic regression, as it is
widely used in prediction modelling despite its problems,
with Bayesian Model Averaging, which can potentially
overcome some of the limitations of stepwise approaches.
The stepwise strategy ignores the variables which are not
selected as well as the uncertainty or imprecision resulting
from the variable selection process itself since the final sin-
gle model is assumed to be “optimal” [19]. Because auto-
mated stepwise variable selection procedures generate a
model to provide the best fit for the available data, there is
the potential that the model will be overfitted and hence
provide an optimistic assessment of its predictive ability
[29]. This “optimism” results in worse prediction in inde-
pendent data [30]. In contrast, BMA selects a number of
all possible single models and uses their posterior probabil-
ities to perform all inferences with the aim of improving
predictive performance [18]. BMA has been shown to be
less likely than stepwise regression to select redundant var-
iables while having a similar probability of selecting a true
predictor [31]. We found that the modelling approaches
that account for model uncertainty out-performed the
stepwise strategy when used to predict MRSA carriage risk.
Similar findings have been demonstrated in other areas of
research such as cardiovascular risk prediction [19].
In our study, targeted screening of patients with predicted
probabilities of MRSA carriage of greater than or equal to
4% would reduce screening burden by about two-thirds
compared with universal screening using both the Stepwise
and Simple models. However, the Simple model was more
sensitive, identifying 6.1% more MRSA carriers. The ration-
ale for the Simple model was twofold. First, it accounted for
model uncertainty by incorporating the BMA approach in
the strategy. It also included covariates that were selected in
the majority of models on repeated random sub-samples of
the data with the aim of identifying factors that were truly
informative since repetition of the procedure allowed moreof the data to be used for derivation of the models. Second,
it was expected that this approach would result in a more
parsimonious model containing fewer covariates as it only
included those that were commonly selected by both Step-
wise and BMA models. This “simple” model would reduce
the risk of overfitting. Indeed, this approach produced the
model with the best predictive performance. A “simple”
model would also be easier to implement in the clinical set-
ting as the number of variables for which information would
need to be collected would be smaller.
The risk of overfitting a model increases if the number of
outcomes is small [32]. Thus the performance of predictive
models developed from cohorts with high MRSA preva-
lence would be expected to be superior to that of models
based on cohorts with few MRSA positive subjects. Indeed
this was demonstrated in our evaluation of model perform-
ance where each hospital was used in turn as the validation
dataset. The number of MRSA-positive subjects was lowest
in the Barcelona cohort in which only 9 (1.8%) patients
were MRSA positive compared with 20 to 51 (2.4% to
5.2%) MRSA carriers in the other hospitals. This difference
in MRSA prevalence may explain why the models did not
perform well, as measured by the c-statistic, except when
data from Barcelona were used in the validation rather than
the derivation dataset. The superior performance of the
models to predict MRSA carriage in the Barcelona cohort
could also be explained by the relatively homogenous group
of MRSA patients in this hospital. Most patients had the
“typical” risk factors of older age, recent hospitalisation,
nursing home residency and presence of wounds.
We evaluated the clinical implications of using each
model compared with the Stepwise model by quantifying
the reclassification of patients into appropriate risk
groups. Our results showed that a cut-off of 4% for the
predicted probability of MRSA carriage would classify
33.2% of patients as high-risk using the Stepwise model.
These patients could be targeted for screening. However,
compared with the Stepwise model, use of the Simple
model would increase appropriate patient screening by
approximately 6.6% (P = .07). This improvement in re-
classification of patients with the Simple model occurred
despite little change in the c-statistic, demonstrating that
the traditionally used c-statistic may be an insensitive
measure of model performance. Novel measures, such as
the NRI, may be more useful for comparing prediction
models [23,33]. Once the model is chosen, the risk cut-
off selected for the screening algorithm will be a trade-
off between the sensitivity and specificity, and where this
cut-off is set is an economic decision which should
ideally be evaluated using decision models.
We explored risk factors for MRSA carriage in a number
of surgical units in different countries using a large sample
size, reducing the risk of overfitting the models. Previous
studies have limited their analyses to single centres or a
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addition, we included subjects who were expected to have
varying levels of MRSA carriage risk. The data used in the
study was also collected prospectively, increasing the qual-
ity of the information on risk factors. We screened at least
two anatomic sites for MRSA carriage as well as using
overnight enrichment for screening specimens [21,34], in-
creasing the sensitivity of MRSA detection. Screening for
MRSA from nasal samples alone or with less sensitive la-
boratory techniques may underestimate true MRSA car-
riage rates and lead to differences in results between
studies. We attempted to correct for overoptimistic model
predictions by cross-validation. In addition, we assessed
the performance of the models in different patient groups
by using each hospital in turn as the validation set.
Our study has some limitations. The predictive per-
formance of the models may be affected by the emer-
gence of community-associated MRSA which, in some
regions, is now the commonest cause of soft tissue infec-
tion among persons who have not had healthcare con-
tact [35]. Livestock-related MRSA is also an increasing
problem in some countries [36]. These emerging strains
of MRSA are not necessarily associated with the traditional
risk factors of healthcare-associated strains. However, in
the 4 hospitals participating in our study, these new MRSA
strains remain relatively rare [37]. It would be important to
externally validate our predictive models, using a dataset
different in time and place to the one from which it was
developed, to determine if their performance properties are
maintained in, and therefore generalisable to, different
patient populations [38]. Geographic variations in MRSA
epidemiology may warrant the development of local pre-
diction rules to increase the accuracy of risk stratification
for selection of patients for MRSA screening.
Conclusions
Multidrug-resistant organisms are an increasing global prob-
lem [39]. Risk prediction models which can accurately quan-
tify the probability of carriage with these organisms can
assist in targeting active surveillance and control measures,
thus increasing the cost-effectiveness of these interventions
[40]. It is important to note, however, that the performance
of different model selection approaches to develop MRSA
risk indices varies. Our study showed that although the pre-
dictive performance of the various approaches was limited,
simpler or more parsimonious models, which account for
model uncertainty, may perform better than commonly-
used stepwise models when assessed with novel, clinically
relevant performance measures. With emerging evidence to
support preoperative interventions to reduce infections in
individuals colonised with S. aureus [9,41], the development
of robust risk profiling tools to identify carriers of both
methicillin-sensitive as well as methicillin-resistant S. aureus
would be an important focus for future research.Abbreviations
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